PMID- 37741537
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20231023
IS  - 1872-7786 (Electronic)
IS  - 0009-2797 (Linking)
VI  - 384
DP  - 2023 Oct 1
TI  - Oral administration of sophoricoside (SOP) inhibits neuronal damage and 
      neuroinflammation to curb neurodegeneration in Parkinson's disease.
PG  - 110726
LID - S0009-2797(23)00393-9 [pii]
LID - 10.1016/j.cbi.2023.110726 [doi]
AB  - Neuronal apoptosis and neuroinflammation are key factors involved in the 
      pathological changes of Parkinson's disease (PD). Sophoricoside (SOP) has shown 
      anti-inflammatory and anti-apoptosis effects in various diseases. However, the 
      role of SOP in PD has not been reported. In this experiment, we found that oral 
      administration of SOP alleviated weight loss and motor symptoms in 
      1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)-injected mice. Further 
      studies revealed that SOP inhibited inflammatory responses and neuronal apoptosis 
      in the midbrain region of MPTP-injected mice. In vitro mechanistic study, we 
      found that SOP exerts neuroprotective effects through a two-sided action. On the 
      one hand, SOP inhibits Lipopolysaccharide (LPS)-induced inflammatory responses in 
      microglia by inhibiting the Nuclear factor kappa-B(NF-kappaB) pathway. On the other 
      hand, SOP inhibits 1-methyl-4-phenylpyridinium (MPP(+))-induced neuronal 
      apoptosis by regulating the Adenosine 5'-monophosphate (AMP)-activated protein 
      kinase (AMPK)/mammalian target of rapamycin (mTOR) signaling pathway. Thus SOP is 
      expected to be a potential therapeutic agent for PD by targeting 
      neuroinflammation and neuronal apoptosis.
CI  - Copyright (c) 2023. Published by Elsevier B.V.
FAU - Wang, Hefei
AU  - Wang H
AD  - College of Veterinary Medicine, Jilin University, Changchun, China. Electronic 
      address: 15754346935@163.com.
FAU - He, Dewei
AU  - He D
AD  - College of Animal Science, Jilin University, Changchun, China. Electronic 
      address: m13144303829@163.com.
FAU - Li, Zhe
AU  - Li Z
AD  - College of Veterinary Medicine, Jilin University, Changchun, China. Electronic 
      address: lizhe9920@163.com.
FAU - Gao, Xiyu
AU  - Gao X
AD  - College of Animal Science, Jilin University, Changchun, China. Electronic 
      address: xiyugdd@163.com.
FAU - Yang, Shuo
AU  - Yang S
AD  - College of Animal Science, Jilin University, Changchun, China. Electronic 
      address: 15204461165@163.com.
FAU - Cui, Mingchi
AU  - Cui M
AD  - College of Veterinary Medicine, Jilin University, Changchun, China. Electronic 
      address: 17649607145@163.com.
FAU - Ye, Bojian
AU  - Ye B
AD  - College of Veterinary Medicine, Jilin University, Changchun, China. Electronic 
      address: yebj871781602@163.com.
FAU - Huang, Bingxu
AU  - Huang B
AD  - College of Animal Science, Jilin University, Changchun, China. Electronic 
      address: huangbx16@mails.jlu.edu.cn.
FAU - Fu, Shoupeng
AU  - Fu S
AD  - College of Veterinary Medicine, Jilin University, Changchun, China. Electronic 
      address: fushoupeng@jlu.edu.cn.
FAU - Liu, Dianfeng
AU  - Liu D
AD  - College of Animal Science, Jilin University, Changchun, China. Electronic 
      address: ccldf@163.com.
LA  - eng
PT  - Journal Article
DEP - 20230921
PL  - Ireland
TA  - Chem Biol Interact
JT  - Chemico-biological interactions
JID - 0227276
RN  - 0 (sophoricoside)
RN  - 9P21XSP91P (1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
RN  - 0 (NF-kappa B)
RN  - R865A5OY8J (1-Methyl-4-phenylpyridinium)
RN  - 0 (Neuroprotective Agents)
SB  - IM
MH  - Mice
MH  - Animals
MH  - *Parkinson Disease/metabolism
MH  - Neuroinflammatory Diseases
MH  - 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine/metabolism/pharmacology/therapeutic 
      use
MH  - NF-kappa B/metabolism
MH  - 1-Methyl-4-phenylpyridinium
MH  - Administration, Oral
MH  - Mice, Inbred C57BL
MH  - Disease Models, Animal
MH  - *Neuroprotective Agents/pharmacology/therapeutic use/metabolism
MH  - Microglia
MH  - Dopaminergic Neurons
MH  - Mammals/metabolism
OTO - NOTNLM
OT  - AMPK/mTOR
OT  - Neuroinflammation
OT  - Neuroprotection
OT  - Parkinson's disease
OT  - Sophoricoside
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/09/24 00:41
MHDA- 2023/10/23 01:18
CRDT- 2023/09/23 19:17
PHST- 2023/05/06 00:00 [received]
PHST- 2023/09/09 00:00 [revised]
PHST- 2023/09/20 00:00 [accepted]
PHST- 2023/10/23 01:18 [medline]
PHST- 2023/09/24 00:41 [pubmed]
PHST- 2023/09/23 19:17 [entrez]
AID - S0009-2797(23)00393-9 [pii]
AID - 10.1016/j.cbi.2023.110726 [doi]
PST - ppublish
SO  - Chem Biol Interact. 2023 Oct 1;384:110726. doi: 10.1016/j.cbi.2023.110726. Epub 
      2023 Sep 21.